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Drug delivery via the pulmonary route has increasingly received much attention in recent years. 
Inhalable particles that are capable of reaching the deep lungs for the intended application can 
be achieved by particle engineering methods and use of appropriate inhalation device.  
This study seeks to develop a carrier-free formulation for poorly water soluble drugs with 
desirable aerosol properties for pulmonary therapy. The Active Pharmaceutical Ingredients 
(APIs) used in this work, Pirfenidone and Budesonide are treatment drugs for some pulmonary 
diseases hence their delivery via the pulmonary route will be better suited for fast local action.   
Carrier-free drug powders were formulated using particle engineering methods to achieve the 
desirable aerosol properties for inhalation therapy. The aerosol flow reactor method was 
utilized in this study and the leucine coating on the powder particles were formed by physical 
vapour deposition of leucine. Prior to the aerosol flow reactor step, precursor solutions were 
prepared with varying concentrations of leucine and also an exogenous surfactant, 
Dipalmitoylphosphatidylcholine (DPPC). The precursor solutions were prepared by wet 
milling of leucine and DPPC in ethanol. The drug was then added to the milled suspension to 
get the precursor solution ready for the aerosol process. In the aerosol flow reactor, the leucine 
formed nanocrystals which were deposited onto the dried drug particles by physical vapour 
deposition (PVD). Two poorly-water soluble drugs were formulated using varying leucine 
concentrations and the resulting powders were investigated with different inhalers for their 
aerosolization behaviours. The morphologies of the coated fine powders were also studied by 
scanning electron microscopy.  
Pirfenidone powders showed agglomerated particles with the degree of agglomeration 
increasing with decreasing leucine concentration. This made the powders less flowable and 
dispersible, but the deagglomeration principle of the inhalation device improved the 
aerosolization properties. The powder with less leucine content had agglomerates which were 
rather difficult to separate even with the inhalation device’s deagglomeration principle. The 
particle size distribution was much higher and most likely to be too large for inhalation. The 
Budesonide particles, having sustained the heat in the aerosol flow reactor showed much 
spherical particles with minimal surface contact. The powders showed good aerosolization 
properties for deep lung deposition. The particle size distributions of all Budesonide powders 
with leucine coating were also well within the appropriate inhalable range.   
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1. INTRODUCTION 
Recently, pulmonary drug delivery has gained an immense interest as a quick and effective 
way for treatment. Many reasons that account for this discovery include patient acceptance of 
this technique due to great advancement in the devices used in pulmonary drug delivery [1]. 
Not only has this technology been attractive for patients and health professionals, but also the 
fact that lungs provide high surface area with moist and highly vascularised tissues for fast 
absorption even with low doses of the drug.[2]  These features of the lung tissues make the 
pulmonary route of drug delivery a promising alternative than  other routes such as intravenous 
and traditional oral route of drug delivery, especially for treatment of pulmonary diseases and 
also to administer insulin in diabetics.[3], [1] In the treatment of pulmonary infections, drug 
delivery via the pulmonary route is most attractive as the treatment targets the disease site 
directly. [4]  
For drugs with a narrow therapeutic window, the pulmonary route helps to moderate the 
systemic side effects as there is reduced systemic exposure because the drug is targeted to the 
infected site. [5] There is also the benefit of eliminating side effects of drug excipients 
especially for patients who are unable to respond well to the presence of the excipients, example 
is lactose intolerance and the use of lactose carriers. It has also been reported that some 
systemic diseases can be well treated by pulmonary drug delivery. Such treatments include 
systemic use of insulin [6], growth factors and oxytocin, all of which are injected intravenously. 
This discovery makes pulmonary drug delivery attractive to patients as a non-invasive method 
of drug administration. [4] Pulmonary delivery of drugs, unlike oral drug administration is 
without hepatic first-pass metabolism [5], [7], [8], independent of dietary complications and 
also differences in patient metabolisms that influence gastrointestinal absorption. [8] 
The aerodynamic features of drug particles used in Dry Powder Inhalation (DPI) therapy play 
a very important role in the delivery of the drug to the lungs. For drug particles to successfully 
reach the lungs for deposition, the particle size should be approximately 0.5-5µm. [9], [10] Size 
reduction and particle engineering techniques such as jet milling, wet polishing or spray drying 
are available to achieve the desired particle size [11]. However, there is the tendency of such 
fine particles to have much stronger co- and adhesive forces and form agglomerates caused by 
Van der Waals forces [12] due to the light weight of the particles. These agglomerates are 
unable to reach the lungs when the drug is inhaled, but rather stick to the upper airways. Fine 
particles are often formulated with coarser excipient particles such as lactose for accurate 
reproduction of drug dosing upon patient’s inhalation [10] [2] On inhalation, the fine drug 
particles need to be separated from the carriers for deep lung deposition. This deagglomeration, 
however, is not often successful due to the above mentioned interactions leading to poor drug 
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delivery. Therefore, coated carrier-free powders are preferred where the fine drug particles are 
coated with crystals to achieve a rough nano-sized surface which reduce agglomeration and 
improve aerosolization of the particles. Particle engineering techniques to obtain spherical 
particles also tend to reduce agglomeration. [13] Particle agglomeration can also be reduced by 
co-formulation with force control agents (FCAs) or lactose particles and low density additives 
such as L-leucine. Alternatively, other forms of mannitol and indigenous lung materials like 
dipalmitolphosphatidylcholine (DPPC) can be replaced with the lactose. [14] 
In this project, DPPC a naturally occurring phospholipid in the lungs is used as an exogenous 
surfactant to carry poorly water soluble drug particles coated with water soluble L-leucine 
nanocrystals for proper deposition and greater bioavailability in the lungs. Coating can be 
performed on any solid particles. A precursor solution is preformulated to combine the carrier, 
DPPC, L-leucine and poorly water soluble drug which do not have similar solubilities.  The 
resulting precursor solution with required particle concentration is then ready for the aerosol 
processing to produce a well flowable and dispersible powder of drug particles coated with 
leucine nanocrystals. DPPC is the most abundant pulmonary surfactant and has been used 
clinically as a non-toxic exogenous surfactant [15].  
There has recently been an increase in the number of candidates described as poorly water 
soluble drugs in drug discovery. The poor dissolution property of the drugs makes them less 
bioavailable. Formulation development methods which improve the solubility of these drugs 
in turn enhance their bioavailability. [16] Growing interest in pulmonary drug delivery also 
coincides with new active pharmaceutical ingredients (APIs) with low and/or inconsistent 
bioavailability. Once an inhaled API has by-passed pulmonary barriers and reached the alveolar 
region of the lungs, it needs to be absorbed. Gastrointestinal (GI) mechanisms of drug 
absorption form the basis of explaining pulmonary drug absorption. [17] Main differences in 
these two routes remain the lungs’ different physiologic and cellular structures with higher 
surface area and thin alveolar-blood barrier [5], [17] for faster absorption than the GI tract. 
However, there is very little physiological significance of drug solubility when administered 
via the pulmonary route because of the presence of low masses of inhaled drug doses, and a 
small but well distributed fluid volume in the lungs. [17] This study employs excipient 
combination using leucine and DPPC for improved aerodynamic performance and stabilise 
physical/chemical properties of the poorly-soluble drugs. 
AIMS: This work seeks to develop a carrier-free formulation technology for poorly soluble 
drugs with desirable aerosolization properties to be used in inhalation therapy. The study aims 
to produce drug powders using particle engineering technologies to enable the powder 
formulation to be properly inhaled into the deep lungs with the proper dosing and dispersibility 
without any carrier particles. 
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2. PULMONARY DRUG DELIVERY 
2.1.1. Anatomy, physiology and histology of pulmonary system 
The prominence of pulmonary drug delivery is expected to remain increasing exponentially for 
the treatment of pulmonary and systemic diseases. The lungs have a large surface area which 
provides them the prospect to be an effective systematic delivery system. [18] [19] In humans, 
the lungs are known to have about 2300 km of airways and 500 million alveoli. There is 
approximately 70-140 m2 of surface area in the adult human lungs. [20] The lungs, as part of 
the lower respiratory tract contain bronchial tubes and millions of air sacs called alveoli. The 
functional unit of the lungs is a respiratory lobule (pulmonary acinus), which contains the 
respiratory bronchioles as well as any associated alveoli. The alveoli are responsible for gas 
exchange during respiration. About 87% of the total lung volume is estimated to be alveolar, 
6% composed of tissue and the remaining 1% is gas. [21] [22] Figure 1 illustrates the 
anatomical features of the human pulmonary system. 
 
 
Figure 1. Anatomy of respiratory system [23] 
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In the alveoli, there are the simple squamous epithelial type I and also the cuboidal 
surfactant septal cells (type II) of the alveoli. [23] Ciliated epithelial cells of larger and 
smaller airways and types I and II cells play a major role in pulmonary drug delivery.  Of 
the two main components of the alveolar epithelium, the type I pneumocytes consist of 
about 95% of the entire alveolar surface and only 5% being type II cells. [20] A thin layer 
of tissue fluid lines within each alveolus, which is important for gas exchange because a 
gas needs to dissolve in a liquid to be able to enter or exit a cell. Surface tension of the 
tissue fluid makes inflation impossible for the alveolar sacs but this problem is resolved by 
pulmonary surfactant, produced by the type II pneumocytes. The surfactant mixes with 
tissue fluid in the alveoli to reduce the surface tension and keep the alveolar sac open. [23]  
Pulmonary surfactant layer comprises about 90% phospholipid and 10% surfactant proteins 
[3], [24]. The surfactant proteins (SP) consist of 4 specific proteins (SP)- A, B C and D [3]. 
The phospholipids work together with the lipophilic surfactant proteins, (SP) -B and -C, to 
lessen surface tension and avoid alveolar collapse. Hydrophilic surfactant proteins (SP) -A 
and -D a major role in immune response as they are capable of binding to particulates such 
as bacteria, viruses or allergens and modulate their interactions with lung cells and also 
immune response leading to enhanced clearance of pathogens. [3] With a transmission 
electron microscope, surfactant can be observed as an extremely thin (4nm) layer that 
covers the alveolar epithelial surface [21]. Figure 2 shows an electron micrograph of type 
II pneumocytes with secretory granules and figure 3 illustrates the entire lung surfactant 
system. 
 
 
Figure 2. Electron micrograph of type II epithelial cells with secretory granules (arrows) [21] 
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Figure 3. Lung surfactant system [25] 
 
In the alveolar airspaces there are large migratory phagocytes moving easily throughout the 
alveolar airspaces and interstitium, known as the alveolar macrophages. They function 
primarily as a clearance mechanism to engulf and digest microorganisms and foreign materials 
present in the lungs. [26] Once in the airspace, particularly after engulfing materials, alveolar 
macrophages do not travel through the intact alveolar or bronchial epithelial layer back into the 
interstitium [27]. 
 
2.1.2. Factors affecting pulmonary drug delivery 
As a rapidly increasing drug delivery route of interest, pulmonary drug delivery still faces some 
challenges despite the numerous advantages it provides [7]. The general effectiveness of an 
inhalation system is known by the mathematical model of the product of fraction of the emitted 
dose (ED), the dose delivered to the lungs and the bioavailability in the lungs [14]. For efficient 
development of inhalation treatments for both local and systemic therapeutics, it is important 
that the entire system of drug, drug formulation and delivery device is optimized and well-
designed [2]. Not only do drug formulations and delivery devices affect aerosol therapies, but 
physiological factors also influence the effectiveness of aerosolized medications [2], [7], [8].  
The physiology of the lungs is designed to keep foreign particles out of the body. Drug delivery 
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by inhalation needs to overcome this physiological barrier. [10] Improvement and assessment 
of innovative aerosol formulations involve understanding the deposition and passage of drug 
molecules across the lung epithelial layer.  Before drug molecules administered via the 
pulmonary route get to the epithelial cells for absorption, they need to overcome certain non-
epithelial barriers which include surfactant, alveolar macrophages and mucus. [7], [8]. 
 In the upper airways, there is mucociliary clearance where inhaled particles of larger sizes are 
removed via the mucociliary escalator. The particles are usually conveyed to the glottis where 
they are either swallowed or expectorated. [24] In diseases such as cystic fibrosis, asthma, cilia 
syndrome and bronchiectasis, mucociliary clearance is impaired. [8] With the correct particle 
size, shape and density, inhaled particles overcome this mucociliary barrier and are deposited 
deeper in the lungs [3], [24].  Several particle engineering techniques are available to achieve 
the appropriate particle size, shape and other characteristics. 
However, these smaller inhaled drug particles are also subject to alveolar clearance by the 
alveolar macrophages after they are deposited deeper in the lungs or absorbed into the 
pulmonary circulation.[8], [28] Alveolar macrophage is a major lung clearance mechanism can 
affect drug delivery to the lungs because they serve as the first line host defence against any 
inhaled particles.[7][24] Small soluble particles tend to be phagocytosed by alveolar 
macrophages more than larger insoluble particles[5]. Soluble particles are easily dissolved and 
absorbed into the lungs epithelium while poorly soluble particles need to be dissolved before 
absorption [8]. For drugs intended for local action, the immediate clearance is a problem 
because when the particles are phagocytosed, they may be transported into the systemic 
circulation and cleared from the lung tissue [5]. 
Pulmonary surfactant, a lipid-protein constituent of fluid layer that covers the respiratory 
surface aids in cell signalling and has an effect on the absorption of inhaled drug particles [3], 
[8], [24]. In some respiratory diseases (for instance Infant Respiratory Distress Syndrome, 
IRDS), the normal functionality of a surfactant system is impaired and this causes a rise in the 
air-liquid interface of the lungs. The deficiency of active surfactant system will gradually result 
in the progressive weakening of lung function. In cases such as IRDS, exogenous surfactant 
therapy can be applied with minimal side effects. [24], [29] Surfactants, with both lipophilic 
and hydrophilic components can enhance emulsification as the interfacial tension between 
water and organic solvents is reduced. This feature of surfactants helps to stabilize and 
solubilize poorly water soluble drug particles, reducing their aggregation. [29] Drug delivery 
with pulmonary surfactants is often desired since the presence of the surfactant could act as a 
substitutive material when endogenous surfactant is damaged or as an additional therapeutic 
agent when surfactant replacement therapy (SRT) is needed [24], [29]. 
Inhalation powder formulations need to contain an active pharmaceutical ingredient (API) in 
the required aerodynamic size distribution for successful deposition in the required target area 
at the flow rate of inhalation [30]. In in-vitro studies, the emitted dose from an inhaler (ED) 
and fine particle fraction (FPF) which describes the alveolar deposition of fine particles are 
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measured using a multistage cascade impactor [14]. The FPF is the measured mass of particles 
with reference to the ED. The mass median aerodynamic diameter (MMAD) of the inhaled 
particles are essential for effective delivery of drugs to the lungs. MMAD, derived from the 
mass, diameter and density of the particles is usually the form in which the aerodynamic 
diameter of particles is expressed. [31] [14] Aerodynamic diameter is the diameter of a 
spherical particle of a unit density which achieves the same velocity in upstream air as a non-
spherical particle of ununiformed density. Smaller aerodynamic diameter of drug particles can 
be achieved by micronization methods such as jet-milling. Reduction of both aerodynamic 
diameter and density of particles are recently achieved by spray drying and spray-freeze drying.  
Surface energies of powder drug particles affect the drug’s effectiveness as increased surface 
energy enhances interparticulate interactions. This is why FCAs such as magnesium stearate 
and low density additives like L-leucine are formulated with inhalation drugs. [14] When drug 
particles are in the preferred size range of 1-5µm, their surface electric forces and Van der 
Waal’s forces surpass the gravitational force acting on them. This results in the particles 
cohesiveness and poor flowability [2][5]. To resolve this problem, coarser lactose particles are 
blended with the drug particles for proper deep lung deposition. Fine particles with a mean 
diameter of 1-5µm can be surface engineered to achieve a rough surface to reduce 
agglomeration of the particles when inhaled. This technique is a carrier-free alternative to 
mixing fine drug particles with coarser lactose particles for the same result of improved powder 
fluidization. [32]  
Inhalation device and inspiratory flow of the patient also affect the effectiveness of inhaled 
drug [33]. In most DPIs, successful deposition of inhaled drugs is improved by fast inhalation. 
Large powder agglomerates from DPIs and sometimes the presence of coarser lactose 
molecules make penetration into lung tissues difficult. The distribution of the powder into 
separate fine particles is often dependant on the turbulent air flow within the inhalation device. 
The turbulent airstream cause agglomerates to break apart and also separate the coarse carrier 
from the drug particles. [2] Each DPI has an airflow resistance that runs the necessary 
respiratory effort. In high resistance DPIs, it is more challenging to create an inspiration flow 
rate that is sufficient enough to attain maximum dose from the DPI. High-resistance DPIs affect 
particle dispersion even at lower inspiratory rates. [33] 
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2.2. Solubility and Bioavailability of Drugs 
From the biopharmaceutical point of view, there are four different categories of drug 
substances and this grouping system is in direct relation to the formulation designs of the 
various groups [16]. The drugs are classified based on their solubility and bioavailability 
properties. This is known as the biopharmaceutics classification system (BCS). The solubility 
of a drug in water plays an important role in its absorption especially after oral administration. 
[34] A drug is classified as highly permeable when the degree of absorption in the intestines is 
found to be at least 90% of the administered dose.  
A highly soluble drug is one whose highest dose strength is soluble in 250ml or less aqueous 
media within the pH range of 1.0 – 7.5 at 37°C. This is because the amount of fluid available 
in the upper gastrointestinal tract is 250ml in a fasted state. Outside of these conditions, the 
drug substance is considered poorly soluble. [16] [34] These reasons also account for the 
expanded interest even in systemic drug delivery via the lungs as these conditions seen in oral 
administration of drugs are eliminated in pulmonary drug delivery [9]. Table 1 below shows 
the various classes of drugs based on bioavailability according to the BCS. 
Table 1. Biopharmaceutics Classification System (BCS) of drugs [16] [34] 
 High Solubility Low Solubility 
High Permeability  Class I 
Immediate release (IR) Solid 
Dosage forms such as 
conventional tablet or 
capsule formulations. 
For oral absorption, there is 
no rate-limiting step. 
Class II 
Dissolution is a rate-limiting 
step in bioavailability so 
even a small increase will 
result in dissolution rate 
becomes a great 
bioavailability enhancement. 
Factors such as effectiveness 
of the surface area, thickness 
of the diffusion layer, 
diffusion coefficient, 
saturation solubility, amount 
of dissolved drug and 
amount of dissolution media 
control the drug dissolution 
rate. Formulation design 
with techniques such as 
micronization, crystal 
modification and self-
emulsification are very 
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helpful in overcoming 
solubility issues. 
Low Permeability Class III 
The bioavailability of these 
drugs is rate-limited by 
membrane permeability in 
the GI tract. Lipophilic drugs 
often have higher membrane 
permeability than 
hydrophilic drugs. 
Surfactants, lipids and bile 
salts are some permeation 
enhancers that can be 
preformulated with such 
drugs to improve their 
permeabilities. Drugs in 
these category can be 
administered in IR solid 
dosage forms with 
permeation enhancers.  
Class IV 
This category is the most 
challenging as both solubility 
and absorption need to be 
improved for proper 
bioavailability of the drug. 
Here, combination of 
approaches used for Class II 
drugs together with 
permeation enhancers as in 
Class III drugs will help to 
improve bioavailability.  
 
 
2.2.1. Poorly water-soluble drugs for pulmonary delivery 
Solubility is a major challenge as an estimated 40% of drugs are lipophilic and difficult to 
formulate due to their poor solubility in water [35], [36]. In the lungs, however, the meaning 
of low solubility has very little physiological effect on absorption due to small masses in the 
inhaled drug dose and also small, dispersed fluid on the lung surface. Among inhaled poorly 
water-soluble APIs, inhaled corticosteroids are the most common category. [9]Corticosteroids 
are mainly used to treat lung inflammatory diseases, especially asthma. They have been found 
to be lipophilic and also with small molecular weights which make them good candidates for 
passive membrane permeability. An ideal inhaled corticosteroid is sustained in the lung tissue 
for extended time of anti-inflammatory action, but with a low absorption to reduce systemic 
action of the API. [9] Many formulation techniques that target an improved solubility and 
bioavailability of these drugs exist. Most of these techniques are well suited for oral 
administration of the drugs.  
 
 
 
10 
 
The BCS for oral drug delivery could be partially comparable to drugs delivered via the 
pulmonary route for systemic action. There could then be a possibility of associating absorption 
with a rise in solubility/dissolution behaviour for poorly soluble and highly permeable drugs. 
However, for pulmonary drug delivery planned towards localized effects, this comparison is 
not applicable. The reason is due to the fact that stability is necessary between dissolution of 
an adequate amount of drug to perform its pharmacological action and limiting the clearance 
mechanisms to retain a constant concentration of dissolved drug in the lung.  
Hence, for poorly-soluble drugs, an enhancement in their solubility properties and their 
controlled release may be necessary in order augment localized therapy. Considering all these 
parameters, the modification of the aqueous solubility and dissolution profile of a drug through 
the exploitation of formulation technologies might directly influence the lung and systemic 
pharmacokinetics (PK) of the drug, and hence on its pharmacological action. [37] 
 
2.2.2. Methods to improve solubility and bioavailability 
The solubility–dissolution performance of a drug is a crucial factor to its bioavailability. One 
of the most challenges of drug development is an enhancement in the solubility of poorly 
soluble drugs. Methods that normally alleviate solubility issues include micronization, salt 
formation, use of a surfactant and use of prodrugs. According to the IUPAC definition, a 
prodrug is a compound that undergoes biotransformation before exhibiting pharmacological 
effects. It is an inactive compound, when metabolized in the body, produces the intended drug. 
Figure 4 below shows pharmaceutical particle technologies that improve drug solubility and 
bioavailability.   
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Figure 4. Pharmaceutical particle technologies for improved solubility and bioavailability of 
drugs [34] 
 
Other techniques use liposomes, emulsion, micro-emulsion, solid dispersion. Inclusion 
complexation with cyclodextrins (a family of compounds made up of sugar molecules bound 
together in a ring) is practical technique but not generally applicable to all drugs. These 
techniques cannot be applied to drugs which are insoluble in aqueous or organic solvents. 
Nanosuspension technology favour drugs which are hydrophobic but soluble in lipids, and also 
drugs which are insoluble both in water and organic solvents. Nanosuspension is submicron 
colloidal dispersion of pure drug particles, and stabilised by surfactants. In nanosuspensions, 
the particle size distribution of the drug particles is typically less than one micron and the mean 
particle size ranges between 200 and 600nm. The purpose of a nanosuspension is not only 
limited to resolving poor solubility issues, but also modification of the pharmacokinetics of the 
drug enhancing drug effectiveness and safety. Nonetheless, these techniques have certain 
limitations and thus cannot be applied to various molecules. [38], [39], [40]  
In the last ten years, nanoparticle engineering methodologies for pharmaceutical applications 
have been developed. Particle technology methods such as particle size reduction and particle 
engineering greatly enhance drug solubility and bioavailability, and is applicable to pulmonary 
drug delivery. The use of nanosuspension technology is also a good approach towards 
pulmonary administration of drugs with poor solubility. Nanosuspensions are made of nano-
sized particles of the poorly soluble drug, without any matrix material, and is suspended in 
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submicron dispersions, and stabilized by surfactants. This is mostly beneficial in pulmonary 
drug delivery for local action. [38], [40] 
 
2.3. Formulation Design of Poorly-Water Soluble Drugs 
2.3.1. Excipients as carrier mechanisms 
Excipients are inactive constituents which are deliberately included in drug formulations but 
do not apply therapeutic effects at the anticipated usage, though they can enhance product 
delivery and efficacy. They also may stabilise the physical and chemical properties of the API, 
and improve its mechanical and pharmaceutical properties such as dissolution permeation 
through the cells. There is a limited number of approved excipients for inhalation drugs. Table 
2 gives a list of such approved excipients and others of major interest.  
Table 2. List of approved and interesting excipients for DPI formulations [41] 
Excipient Description Status 
Sugars 
 Lactose 
 Glucose 
 Mannitol 
 Trehalose 
Used as coarse/fine 
carrier 
Lactose is approved and 
commonly used carrier 
Glucose is approved 
Mannitol is approved 
Trehalose is an 
emerging alternative 
Hydrophobic additives 
 Magnesium stearate 
Protect drugs from 
moisture 
Approved 
Lipids 
 DPPC 
 Distearoyl-sn-glycero-3-
phosphatidylcholine (DSPC) 
 Dimyristoylphosphatidylcholine 
(DMPC) 
 Cholesterol 
Used in liposomes, 
matrix, coating 
Biocompatible and 
biodegradable, very 
interesting excipients 
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Amino acids 
 Leucine 
 Trileucine 
Enhanced aerosol 
efficiency 
Endogenous substance, 
no data on lung toxicity 
Surfactants 
 Poloxamer 
 Bile salts 
Producing light, 
porous particles 
Poloxamer may not be 
pro-inflammatory at low 
doses. 
Bile salts are 
endogenous substances 
which may be accepted 
at low doses. 
Absorption enhancers 
 Hydroxypropylated-β-CD, 
natural γ-CD 
 Bile salts 
 Chitosan, trimethylchitosan 
Absorption for 
proteins and 
peptides 
Hydroxypropylated-β-
CD, natural γ-CD 
yielded promising result. 
Bile salts also yielded 
promising results but 
may be toxic in chronic 
use. 
Pro-inflammatory 
results have been 
observed with chitosan 
and trimethylchitosan 
 
Biodegradable polymers 
 Poly(lactic-co-glycolic) acid 
(PLGA) 
Used in sustained 
drug formulations 
Immunogenicity effect 
observed 
 
Excipient combinations can be employed to further improve the performance of inhalation 
powder formulations. With a greater flexibility in particle engineering techniques to explore 
excipient combinations, it is more likely to find a more suitable and acceptable formulation for 
further product development. [42]  
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2.3.2. Particle engineering  
Conventional inhalation powder formulation technologies such as jet milling often have 
limitations due to their difficulty in formulating therapeutics. Recent innovations in particle 
engineering aim to overcome such limitations with limited or no carrier excipients. In addition, 
the use of carrier-free formulations allows for an improved delivery of inhaled drugs that are 
required in high doses, such as with antibiotics delivery. [42], [43] Most commonly used 
particle engineering methods include emulsion, supercritical fluid and spray/freeze-spray 
drying. Emulsion based systems have been shown to produce spherical particles from non-
miscible solvent emulsions generation by sonication or homogenization. The solid composite 
particles produced are often dense and have a narrow particle size distribution.  
Emulsion-based methods have the disadvantage of being difficult to scale up to commercial or 
industrial scale, as large quantities of the solvents will be required and there is a need for 
effective removal of solvent residues from the products.[10], [42] Based on an anti-solvent 
principle, supercritical fluid processing often uses supercritical carbon dioxide as the anti-
solvent to produce inhalable particles by introducing the drug solution in the direction of the 
carbon dioxide, under supercritical conditions.  
Spray drying is able to produce both low and high density particles. In spray drying, a feed 
solution or slurry is atomised using hot compressed air or gas to produce dry inhalable particles. 
The concentration of the solid particles is determined by the droplet concentration in the 
atomization. When the feed solution is a milled suspension, crystalline particles are produced 
whereas when drug and excipients are molecularly dissolved the resulting particles are 
amorphous. Spray drying can also be applied for heat sensitive materials.  [10], [42] Spray 
drying is a good example of particle engineering technique with the capability of scaling up. 
However, one concern about the spray drying process is the physical and chemical stability of 
the particles. Re-crystallisation often occurs in many amorphous or partly amorphous particles, 
when there is a higher relative humidity (about 70%) causing a moisture-related instability. Co-
spray drying with excipients would help to improve the hygroscopicity of amorphous particles, 
and prevent recrystallization. [44] Spray-freeze drying, a variation of spray drying is a more 
expensive batch process which avoids producing an air-liquid interface by atomizing particles 
into a cryogenic liquid, followed by lyophilisation. Scaling-up to industrial scale could be 
problematic with spray-freeze drying technique, as large volumes of cryogenic liquid may pose 
a safety hazard. [42] 
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2.3.3. Aerosol flow reactor method for DPIs 
An ideal process should be continuous, single-step (that is, from solution to respirable product), 
and tuneable to produce particles with preferred physicochemical and aerodynamic features for 
pulmonary delivery. It should be a process that is able to yield products with a perfect batch-
to-batch consistency, high yield, financially competitive, easily scaled up and appropriate for 
regulatory approval. [10]   
The aerosol flow reactor method is a novel one-step continuous process for micro-particle 
production from drug, excipient and L-leucine liquid solutions.  This method produces 
spherical drug micro-particles, and uses physical vapour deposition to coat the particles with 
L-leucine nano-sized crystals. [45], [46] The aerosol flow technique often avoids the use of 
harsh chemicals/solvents. The prepared drug solution (precursor solution) is atomised by an 
ultrasonic atomiser into droplets. The droplets are then suspended in a carrier gas, fed into a 
heated stainless steel reactor and the particles are collected after being dried inside the reactor. 
The reactor is tubular, with a completely laminar flow in the heated part. The temperature of 
the reactor is adjusted to allow a complete solvent evaporation and particle formation inside 
the reactor. The resulting particles also show spherical and smooth surfaces. [46]. Inside the 
heated part of reactor, the droplets are dried and leucine is evaporated. According to a study by 
Raula et al. in 2008 which investigated the production of leucine nanoparticles at varying 
conditions by the aerosol flow reactor method, growth and particle formation mechanisms of 
leucine nanoparticles depends on the L-leucine saturation conditions present in the reactor. The 
reactor temperature also affects the vaporisation rate of L-leucine. The study suggested that 
higher reactor temperatures of over 150°C to 200°C allows for complete evaporation of leucine, 
regardless of its concentration in the precursor solution. [47]  
At the reactor downstream, the aerosol with dry particles is rapidly cooled and diluted in 
turbulent flow. This section of the reactor is composed of a porous stainless steel tube to avoid 
particle deposition on the walls of the tube and also to initiate the nucleation and deposition of 
L-leucine vapour onto the drug particle surface.[48] Due to the rapid cooling, L-leucine vapour 
begins to nucleate and subsequently crystallize on the surface of drug particles by physical 
vapour deposition (PVD).[49] The size of crystals which varies from a few to hundreds of 
nanometres is controlled by the saturation conditions of L-leucine.  Figure 5 below shows the 
formation of leucine coating on spherical particles at varying conditions according to the study 
by Raula et al. in 2008[45]. 
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Figure 5. Formation of L-leucine particles in an aerosol flow reactor at varying vapour 
pressures [49] 
 
In case I of figure 5, the saturation ratio of leucine (SL) is above unity and no sublimation 
occurs. Upon further increase of the reactor temperature, the droplets were dried and leucine 
was subsequently sublimed. In case 2, SL was close to unity and the sublimation of leucine 
occurred. When the sublimation occurs, it is assumed that the leucine vapour is in close 
proximity to the core surfaces. In case 3, SL is far below unity and that is when all of the leucine 
sublimed. In the cooling segment of the reactor, different leucine particles were produced based 
on cases 1-3.   When sublimation begins as in case 2, there is partial sublimation resulting in 
homogeneous nucleation of leucine.  Two leucine coating layers are formed due to diffusion 
(in case 1) and the partial sublimation to form large leucine crystals. In case 3, pure leucine 
coating formed is due to homogeneous nucleation as well as heterogeneous nucleation onto the 
core particle. 
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2.4. Inhalation Aerosol Devices 
An effective inhalation therapy not only depends on a pharmacologically active material and 
its well-designed formulation, but also on the delivery system. Before modern inhalation 
devices were developed, asthma patients used to smoke asthma cigarettes containing 
stramonium powder and tobacco as a form of treatment back in the 19th and early 20th centuries. 
Pressurized metered-dose inhalers (pMDIs), nebulizers and DPIs are the three major delivery 
systems for modern inhalation therapy. Among them, DPIs have several advantages such as 
good portability, low costs and no use of propellants and also improved stability of the 
formulation due to its dry state. Moreover, DPIs are much easier to handle than pMDIs due to 
breath-actuated passive aerosolization (in DPIs). [50], [51], [2] Figure 6 below illustrates the 
evolution of inhalation devices. 
 
Figure 6. Evolution of inhalation devices [2] 
 
Nebulizers produce an inhalable drug aerosol from a solution or suspension. The two main 
kinds of nebulizers are the jet nebulizer and the ultrasonic nebulizer, with jet nebulizer being 
the most commonly used. The jet nebulizer functions by generating aerosols from the liquid 
drug using a source of compressed gas.  Based on the Bernoulli principle, a compressed gas 
goes through a constricted opening forming an area of low pressure at the outlet of the 
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neighbouring liquid feed tube. The drug solution is then drawn up from the fluid reservoir and 
dispersed into droplets in the gas stream. Ultrasonic nebulizers on the other hand, use 
piezoelectric crystal vibrating at high frequency to create a fountain of drug solution droplets 
in the nebulizer chamber. The higher the frequency, the smaller the droplets. Despite being 
relatively inexpensive, the gas compressors in jet nebulizers are often bulky and noisy. There 
is also the tendency of residual drugs being wasted, making it an expensive delivery system if 
the drug involved is expensive. [2], [52] 
The pMDI was developed to overcome the problem of bulkiness in nebulizers. MDIs emits 
drug aerosol driven by propellants. There has been great improvement in the design of MDI 
propellants from chlorofluorocarbons (CFCs) to more environmentally friendly propellants 
like hydrofluoroalkanes (HFAs). The delivery efficacy of MDIs is dependent upon the 
breathing pattern, inspiratory flow rate (IFR) and hand-to-mouth coordination of the patients. 
Breath-actuated pMDIs have been developed to help patients with poor MDI technique. For 
particle sized within the respirable range of 1-5µm, proper deposition is more dependent on 
IFR than any other parameter. MDIs require slower inhalations to improve the deposition of 
inhaled drug particles in the peripheral regions of the lung. [2] 
DPIs were developed to improve the coordination difficulties faced by using MDIs and also 
eliminate the use of propellants. Unlike MDIs which require inhaling slowly and holding of 
breath to improve lung deposition, proper deposition of drug into lungs is improved by fast 
inhalation with DPIs. [2] The dry powder strategy is characterised by giving the drug to the 
patient in the form of dry powder, administered using a specifically designed device for such 
formulation. Generally, inhalation devices depend on the inspiration flow of the patient for the 
dispersal of the aerosol and deposition into the deep lungs (breath-actuated devices).  Table 3 
summarises the main inhalation devices with pros and cons of each device. 
Table 3. Pros and cons of different inhalation devices [2] 
Inhalation device Pros Cons 
Nebulizers (jet and 
ultrasonic) 
  No specific 
inhalation technique 
or coordination 
needed 
 Able to aerosolize 
most drug solutions 
 Delivers large doses 
 Well suited for 
infants, sick people 
and physically 
 Time consuming and 
noisy 
 Bulky 
 Contents easily 
contaminated 
 Relatively expensive 
(gas compressors) 
 Poor delivery 
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impaired people who 
are too weak to 
handle other 
inhalation devices 
 
efficiency 
 Drug wastage 
 Wide variations in 
performances due to 
difference in models 
and operating 
conditions 
Pressurized metered dose 
inhalers (pMDIs) 
 Compact and 
portable 
 Affordable 
 Repeatable dosing 
Environment is 
sealed therefore there 
is no degradation of 
the drug 
 Multidose 
(approximately 200 
doses) 
 Inhalation technique 
and patient 
coordination 
necessary 
 There is a high oral 
deposition of the drug 
 Maximum dose of 
5mg 
 Restricted range of 
drugs available 
 
Dry powder Inhalers 
(DPIs) 
 Compact 
 Portable 
 Easy to use 
 Breath actuated 
 No hand-mouth 
coordination is 
required 
 Respirable dose 
depends on patient’s 
inspiratory flow rate 
 Humidity may cause 
powders to 
agglomerate and 
capsules to soften 
 Dose lost if patient 
unintentionally 
exhales into inhaler 
 Most DPIs contain 
lactose 
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Aerosolisation behaviours of DPIs depend on the powder formulation as well as the design of 
inhaler devices. [43], [52] Increased humidity and quick temperature changes are known to 
affect the performance of a DPI. The DPI performance can also be affected by the turbulence 
produced inside the device. The device’s turbulence affects the deagglomeration of the 
powdered drug dose and consistency of the inhaled dose. All DPIs present a resistance to air-
flow, and DPIs have been classified on the basis of their resistance and pressure drop across 
the device. [33] It is more difficult for higher resistance DPIs to produce an inspiratory flow 
that is sufficiently high to attain a maximum dose from the inhaler. Nonetheless, higher-
resistance devices improve lung deposition of the powder. [2] Table 4 below summarises the 
various categories of DPIs based on their resistance to inspiratory flow and pressure drop across 
device. 
Table 4. Major categories of DPIs on the basis of their intrinsic resistance and pressure drop 
across the device. [33], [53] 
DPI Type Pressure drop across device 
Low-resistance DPIs < 5Mbar (½) (L/min)-1 
Medium-resistance DPIs 5-10 Mbar (½) (L/min)-1 
High resistance DPIs >10 Mbar (½) (L/min)-1 
 
A DPI is classified as low-resistance when the inspiratory flow of > 90 L/min by the patient is 
required. Medium-resistance DPIs require inspiratory flow of about 50-60 L/min and high 
resistance devices require an inspiratory flow of < 50 L/min for proper lung deposition. An 
ideal DPI should include at least most of the following features: portable and easy to use, able 
to generate a consistent emitted dose across a wide range of inspiratory flows rates, fine particle 
fraction of high reproducibility, high physical and chemical stability of powder, low extra-
pulmonary loss of powder (that is low oropharyngeal deposition, low device retention and low 
exhaled loss). [33], [43]  
There is a demand for DPIs to be consistent in the dosing. The dose measuring mechanism of 
the device is responsible for the dose consistency. In bulk or reservoir type DPIs, a good dose 
counter indicates how many doses are left in the device. It is widely believed that all DPIs 
function best at a pressure drop of 4KPa or flow rate of 60L/min, but studies have shown that 
similar levels of FPFs are observed at relatively low pressure drops of 2-3KPa. A study by 
Hoppentocht et al. in 2014 has categorised DPIs into two classes; those that produce 
approximately the same FPF at different flow rates and those producing higher FPFs with 
increasing flow rates. [30] The perfect inhaler should also provide constant de-agglomeration 
regardless of air flow rate [54] Figure 7 illustrates the main functional features of a typical DPI, 
Turbohaler®. 
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Figure 7. Primary functional design elements of a DPI [12] 
 
A wide range of DPIs exist on today’s market. Based on their dosing system, there are single-
dose system which are loaded by the patient, multiple-unit dose systems that are in the form of 
separately packed doses as capsules, and reservoir type (bulk-powder) systems from which 
specific doses are measured or metered. The single-dose system has the disadvantage of patient 
alertness to load the drug. [2], [12], [43]   
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3. PARTICLE CHARACTERIZATION AND SIZE 
DISTRIBUTION 
3.1. Scanning Electron Microscopy (SEM) 
In electron microscopy, a much higher magnification for better image resolution than the 
conventional optical microscopes (which is only about 1000x maximum) is used. The 
magnification power of SEM can be as high as hundreds of thousand times and uses electrons 
to form an image which tells about the surface structure, crystalline conformation or electrical 
performance of samples. Accelerated high energy electrons with about 2 to 1000keV kinetic 
energies are focussed onto the sample to produce signals which form the image. Electron-
sample interactions lead to image formation in SEM. [55] Figure 8 shows the interactions 
between high energy electrons and atoms of the specimen. 
 
 
Figure 8. Interactions between high energy electrons and atoms of specimen [55] a) Low-angle 
scattering, b) High-angle or back scattering, c) Emission of secondary electrons and 
characteristic x-rays, d) secondary electron and auger electron emission  
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Interactions between electron beam and the specimen can be grouped into two main types 
which are elastic and inelastic interactions. In elastic scattering, the incident electrons are often 
deflected either by the atomic nucleus or electrons of the outer shell with comparable energy 
to the energy of incident electrons of the sample. When this happens, there is usually an 
insignificant energy loss from the collision and there is a direction change at a wide angle of 
the scattered electron. At angles more than 90°, the elastically scattered electrons are known as 
back scattered electrons (BSE) as seen in Figure 8b. [55]– [57] 
Inelastic scattering happens as a result of a number of electron-specimen interactions. The 
quantity of energy loss depends from the collision on how the sample atoms get excited, 
whether singly or collectively and also on the binding energy of the atom. Secondary electrons 
(SE) are electrons that escape from the sample with energy less than 50eV. They originate from 
loosely bound conduction band in metallic sample or the outer shell of semiconductors and 
insulating samples. SEM images are formed from signals of secondary electrons (SE) emission. 
Other signals produced include characteristic x-ray, auger electrons and cathodoluminescence. 
[55], [56] Figure 9 below shows the regions where various signals emerge from.  
 
 
Figure 9. Beam-specimen interaction and regions where detected signals may be emitted [57] 
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With increasing atomic number (of sample), the rate of energy loss of incident beam also 
increases. As a result, electrons are unable to penetrate deeply into the sample causing an 
increase in the likelihood of elastic scattering with increasing atomic numbers. [55] 
In SE signal, secondary electron coefficient (δ) is a ratio of the number of SE to the number of 
incident beam electrons. Due to their low energy levels, SEs usually escape from a shallow 
depth. [55], [56] About 90% of SEs have their energies less than 10eV with majority within 
the 2-5eV range. Since SEs are mainly used for topographical contrast in SEM, the amount of 
SEs reaching the detector plays a major role in the image produced. SEs that are unable to reach 
the detector will form darker shades in contrast than those that easily reach the detector. When 
the surface of the sample is perpendicular to the incident electron beam, the region of the 
sample surface from which SEs emerge from is smaller than when the sample is tilted. In tilting 
the sample surface, electron beam travel greater distances in the surface regions of the sample. 
This will result in more SEs being emitted within the escape depth. [56], [57] BSEs usually 
have higher energies than SEs, hence their (BSEs) inability to be absorbed by the sample. This 
makes the region from which BSEs emit from larger than where SEs are emitted from. As a 
result, the lateral resolution of a BSE image significantly poorer (1.0 μm) than it is for a SE 
image (10 nm). [56] 
SEM images are typically greyscale and interpreting greyscale images requires understanding 
the origin of contrast mechanisms. In the absence of contrast, a high resolution and strong 
signal scan cannot reveal any information. Many microscopes have brightness and contrast 
controls. To manually adjust the controls, contrast should be turned down then brightness 
adjusted until there is a visible image on the screen. After this then contrast is also adjusted to 
obtain a visually appealing image. The surface of the sample may have uneven compositional 
atomic numbers. Some regions will have higher atomic numbers than other areas. Those 
regions with higher atomic number (Z) will emit more BSEs and appear brighter in the final 
image. The number of SEs emitted also increases with increasing atomic number. Hence 
contrast of SE signal and BSE signal can provide information on sample composition. This is 
why Z contrast is also called composition contrast. However, BSE signal gives better contrast 
than SE signal. Z contrast is relatively stronger at lower atomic numbers.  
The microscope consists of seven main operational systems. These are the beam generation, 
vacuum, beam interaction, beam manipulation, detection, signal processing, and display and 
recording system.  Figure 10 illustrates the major components of the SEM. 
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Figure 10. Major components of SEM column and specimen chamber [58] 
A vacuum is often required when using SEM, due to the presence of electrons. Electrons easily 
disperse and collide with other molecules in the absence of a vacuum system. Hence the need 
for a vacuum to focus electron beam onto the specimen. From figure 10, the electron generating 
system can be located above the microscope column. This system produces the primary 
electron beam. The beam manipulation system is made of electromagnetic lenses and coils 
situated in the microscope column. The system controls the size, form and location of the 
electron beam on the sample surface. The beam interaction system encompasses the contact of 
electron beam with the sample and the types of resultant signals from the beam-specimen 
interactions. 
The detection system comprises of various detectors, with varying sensitivity to different 
energies or particle emissions from the sample. The signal processing system processes any 
signal generated by the detection system, and also permits any further electronic manipulation 
of the image. Finally, the display and record systems are for visualizing electronic signals by 
means of a cathode ray tube. The system records the results with photographic or magnetic 
media. [58] 
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3.2. Particle Size Distribution: Berner Low Pressure Impactor (BLPI) 
Measurement of aerodynamic size is mandatory for in all orally inhaled and nasal drug 
particles. Cascade impaction is a well-known technique for such measurement. The operation 
of cascade impactors is based on inertia impaction. On each stage of the impactor, there is a 
single or a series of nozzles. Particles saturated air is drawn through these nozzles on the 
impactor stages. The particles with suitable size in the airstream are directed to the surface of 
the collection plate for that specific stage. The impaction of a particle on a particular stage is 
determined by the particle aerodynamic diameter. Particles with sufficient inertia for a 
particular stage will impact on the collection plate of that stage while smaller particles with 
inadequate inertia stay in the airstream and move on to the next lower stage through the stage 
orifice. [51], [59] 
The stages are put together in a stack by order of decreasing particle size. The largest particles 
are trapped on the highest stage collection plate while the finer particles are passed on to 
subsequent lower stages. [60] Figure 11 shows the flow of particle laden airstream through the 
impactor stages. 
 
 
 
Figure 11. Flow through a cascade impactor [59] 
 
Most experimental and theoretical studies with low pressure impactor are only concerned with 
single orifice impactor stagers. The BLPI comes with a multi orifice stage geometry and used 
extensively in size distribution studies for aerosols. [61] 
According to the American and European pharmacopoeias, inertial impaction based methods 
have been explained to evaluate the in vitro inhalation performance of dry powder formulations 
by determining fine particles. [51], [62] Inertial impaction, is an aerodynamic process governed 
by aerodynamic diameter and allows for determining fine-particle dose (FPD). FPD is 
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equivalent to the mass of drug particles with the capability of deep lung deposition after being 
inhaled (that is, they have an aerodynamic diameter or MMAD of less than 5µm). FPF is a 
percentage of the FPD, and is usually associated with the total mass of drug in the inhalation 
device or drug particles recovered from the different stages of the impactor. FPD and FPF have 
similar functions of determining the ability of the drug formulation to be fluidised and 
disaggregated in time to be deposited at the various stages of the impactor. The dispersion 
performance of a powder formulation is often represented by the FPF. The higher the FPF, the 
better the powder dispersibility. Sometimes, the FPF can be calculated based on the emitted 
dose (ED).  ED is the drug powder mass leaving the device after inhalation. The emitted dose 
reveals the reveals the capability of the powder to be aerosolized by the airflow in the inhalation 
device. [51], [63]  
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4. MATERIALS AND METHODS 
4.1. Particle Preparation 
The drugs studied were Pirfenidone (99%, from Wuhan Benjamin Pharmaceutical Chemical 
Co., China) and Budesonide (98.5%, from Henan Tianfu Chemicals Co., China) powders, both 
of which are used in pulmonary medicine and soluble in ethanol. Pirfenidone is an anti-fibrotic 
medication used for treating idiopathic pulmonary fibrosis (IPF), a severe chronic lung disease. 
According to the European Medicines Agency, it is commercially available under the trade 
name Esbriet® and is administered orally in capsule form for treatment of IPF in adults. Since 
these drugs are used in treating diseases related to the lungs, their administration via the 
pulmonary route could be more beneficial. Figure 12 presents the main stages involved in 
producing coated drug particles with enhanced solubility. 
 
Figure 12. Various steps involved in preparation of leucine-coated drug particles (the lower 
part of the figure is what goes on in step 1) [64] 
 
Mixing the poorly water soluble drug and coating material L-leucine directly to form a 
precursor solution for aerosol process is impossible as they have different solubilities. Hence 
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preformulation is required prior to the aerosol process. This project employs the technique of 
wet milling large leucine crystals with a phospholipid (DPPC) in ethanol, then dissolving the 
poorly water soluble drug in the organic suspension. 
4.1.1. Wet milling 
For the wet milling process, 100g of 3mm diameter zincronium (Zr) beads was weighed into a 
milling chamber of a planetary milling machine (Pulverisette 7 Premium, Fritsch Co., 
Germany), then 6g of powdered leucine was added to the Zr beads in the chamber. 1g of the 
phospholipid, which had been stored in a freezer was brought to room temperature and then 
dissolved in 20ml of pure ethanol. The dissolution process was hastened by heating the beaker 
containing the ethanol and DPPC over a warm water bath. The DPPC solution was then added 
to the leucine and Zr beads in the milling chamber. The counter chamber of the pulveriser was 
weighed and ensured that it was of similar weight to the other chamber containing the milling 
ingredients. Both chambers having similar weights provided a balance on both sides of the 
milling chambers. The chambers were locked in place and the pulveriser was run at 1100rpm 
for 3x3 minutes with 15minutes pause between the runs. The selected ball size was <5mm 
balls.  
The 3x3min cycles were repeated 4 times, allowing the chamber cool for about an hour after 
each 3x3min cycle. After cooling the chamber after the 4th round, the milled slurry was washed 
with ethanol to further prepare the precursor solution. 
 
4.1.2. Preparing precursor solution 
The milled slurry was washed with 180ml pure ethanol and sieved to remove the Zr beads. To 
achieve concentrations of 20g/L drug, 15g/L leucine and 2.5g/L DPPC, 8g of drug and 200ml 
of ethanol were added to the milled suspension. The precursor solution prepared was 400ml in 
volume. This was the first precursor solution ready for the aerosol processing, with a 
leucine/DPPC concentration ratio of 6:1.  
After the aerosol production, remaining precursor solution was subsequently diluted to get 
lower concentrations of leucine and DPPC while maintaining a constant concentration of the 
actual drug by adding more of the drug according to required concentrations. Table 5 below 
shows the various concentrations of precursor solutions prepared for the aerosol process. 
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Table 5. Concentrations of drug, leucine and phospholipid for various precursor solutions 
Drug conc. (g/L) Leucine conc. (g/L) DPPC conc. (g/L) 
20 15 2.5 
20 5 0.83 
20 0.875 0.146 
 
 
4.1.3. Aerosol particle preparation 
The coated drug particles were prepared by the aerosol flow reactor and PVD methods as 
explained in Chapter 2. The aerosol flow reactor of length 150cm and diameter 10cm was 
preheated to 180°C in all three zones (illustrated in figure 13). The precursor solution was put 
into a burette and fed into the ultrasonic atomiser. The atomiser produced solute droplets from 
the precursor solution, and the droplets were carried by nitrogen gas at a flow rate of 20L/min 
into the heated aerosol flow reactor. In the heated section of the reactor, where the flow was 
laminar, the droplets were dried, while leucine completely evaporated and carried to the cooling 
section. By PVD method, the leucine vapour was deposited onto the drug particles forming a 
layer of coating around the spherical particles.  
In the cooling section, the flow was turbulent and dry air at a flow rate of 78L/min was used to 
rapidly cool the dry particles. The large volume of air flushed in prevented water re-
condensation and also prevented the powder particles from sticking onto the walls of the reactor 
tubes at the cooling and collection section. The dried and cooled micro particles were collected 
with a cyclone for small scale purposes. An electric low-pressure impactor (ELPI) was 
connected to the tube linking the reactor cooling section to the cyclone. During the running of 
the reactor, the ELPI valve was opened to monitor the size distributions of the particles being 
produced.  All coated powders produced were stored over silica prior to the dispersion 
experiments. 
The aerosol process was performed for each concentration of precursor solution produced. 
Hence, for each drug studied, three particle samples were produced according to the 
concentrations in table 5.  Figure 13 illustrates a schematic representation of the aerosol flow 
reactor used in particle preparation. 
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Figure 13. Experimental set-up of  the aerosol flow reactor  
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4.2. Dispersion Experiments 
A non-commercial computer assisted inhalation simulator was used to investigate the 
dispersibility of the produced powders. This in-house inhalation simulator [65] which functions 
by an interaction between pressurized air and vacuum, and uses a BLPI attachment as the 
measuring device.  
All the dispersibility experiments were performed with the prepared carrier-free fine powders 
i.e. no coarse carrier particles were added. Two medium-resistance DPIs, a multidose reservoir 
or bulk-type Easyhaler® made by Orion Pharma and single-dose capsule type Twister™ 
inhaler made by Aptar Pharma, were used. Both inhalers are shown in Figure 14 below. The 
Easyhaler reservoir was filled with approximately 0.5g of powder, and Twister with capsules 
filled with 5.0 (±0.1) mg/capsule.  The loaded inhaler was attached to the mouthpiece of the 
inhalation simulator. Each inhaler was attached to a specific mouthpiece which was changed 
upon switching the inhaler. Upon inhalation, air flowing through the inhaler carried the powder 
and transferred it to the tubing of the device.  
 
Figure 14. Left: Easyhaler® by Orion Pharma Oy, multidose inhaler. Right: Twister™ by 
Aptar Pharma, capsule inhaler. 
 
Emission of the powder was sensed on-line by a light attenuation between two contrasting IR 
probes lined at the exit of the inhaler and also by gravimetric means. The inhalation run was 
performed 10 times and for the Easyhaler, the inhaler being held at an upright position was 
shaken vertically 3 times prior to the dose loading and powder inhalation in between the runs 
the inhaler. The shaking process removed possible remnants from the previous loading. For the 
Twister, the inhaler was emptied after each single dose inhalation.  
Before each ten-emission experiment, five emissions were first run to stabilise air flows and 
pressure drops across the device to improve accurate results for the actual experiments. 
Pressure across the inhalers were manipulated to 2kPa and 4kPa, and ten emissions were 
performed on all fine powders at both pressure drops. Fast inhalation profiles were used in all 
dispersion experiments. In a fast inhalation profile, the maximum pressure drops and flow rates 
were attained in two seconds retaining these levels for 9 seconds then quickly dropped down 
and stopped within a second after the 9 seconds. The inhalation profiles were created for both 
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inhalers at different pressure drops were by an interplay between vacuum and pressurized air. 
Figure 15 shows the typical inhalation profiles. 
 
Figure 15. Typical inhalation profile run by the inhalation simulator where blue is flow rate, 
green is pressure drop over the inhaler and red is light detection for the powder emission. 
 
The measured fine particle fractions were expressed in reference to the emitted doses. The EDs 
were evaluated by measuring the weight change of the inhaler after each inhalation run. 
MMADs and their related geometric standard deviations (GSD) were determined through 
gravimetric analysis of aluminium foil rings placed on the collection stages of a ten-stage BLPI. 
The MMAD and GSD were determined by the following expressions: 
MMAD = exp  (
∑(𝑚𝑖 ln 𝐷𝑖)
𝑀
) 
 
GSD = exp ((
∑(𝑚𝑖𝐷𝑖
3 (ln 𝐷𝑖−ln 𝑀𝑀𝐴𝐷)
2)
∑(𝑚𝑖𝐷𝑖
3)−1
)
1/2
) 
Where mi is the mass fraction of fine powder particles on the collection stages of the BLPI, M 
is the sum of mass fractions which is unity by definition. Di is the aerodynamic diameter of the 
ith size stage of the BLPI.   
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4.3. Particle Morphology 
Morphologies of the fine powder particles were studied using a field emission scanning 
electron microscope (Zeiss Sigma VP). In preparing the samples for the SEM imaging, a piece 
of carbon tape was fixed onto a clean SEM pin specimen stub and the thin top layer of the 
carbon tape was carefully removed. Using a spatula, a pinch of the powder sample was then 
sprinkled onto the carbon tape and the stub was carefully tapped to get rid of loose powder 
particles. Compressed air was then used to further blow off excess powder particles, leaving a 
thin layer of powder particles well fixed onto the carbon tape.  
After fixing the sample particles onto the carbon tape, the stubs were placed onto the SEM 
sample stage, metal (gold was used) sputtering was performed to coat the non-conductive 
samples. The gold sputtering was done to reduce charging effects, make the non-conductive 
sample more stable under the electron beam and improve the quality of the image formed. The 
sample stage with the samples was then placed into the SEM specimen chamber for the actual 
imaging. 
 
4.4. Particle Composition 
 
Particle composition were analyzed by 1H-NMR spectroscopy (Bruker 400 MHz UltraShield 
NMR) in deuterated ethanol (Sigma Aldrich). 
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5. RESULTS  
5.1. Particle Composition and Morphology 
5.1.1. Particle composition 
Using nuclear magnetic resonance (NMR) spectroscopy, the compositions of the precursor 
solutions and fine powders were obtained. Due to insolubility of leucine in deuterated ethanol, 
its content in the final powder was determined by back calculating from the precursor solution 
assuming that the leucine/DPPC ratio remains the same in the final powders as it was in the 
precursor solution. Table 6 shows the various compositions in the precursor solutions and 
powders produced from them. 
Table 6. Composition of precursor solutions and produced powders assuming L/Ph ratio 
remains the same in produced powders. Abbreviation: Ctotal, total concentration of precursor 
solution; Pi, Pirfenidone; Bu, Budesonide; L, Leucine; Ph, Phospholipid 
Sample Precursor solution Produced powder 
Ctotal 
(g/L) 
Drug 
(w-%) 
L (w-%) Ph (w-
%) 
Drug 
(w-%) 
L (w-%) Ph (w-
%) 
Pi20L0.875Ph0.146 37.50 95.1 4.2 0.7 87.8 10.4 1.7 
Pi20L5Ph0.83 25.83 77.4 19.4 3.2 64.2 30.7 5.1 
Pi20L15Ph2.5 21.02 53.3 40.0 6.7 35.6 55.2 9.2 
Bu20L0.875Ph0.146 37.50 95.1 4.2 0.7 82.4 15.1 2.5 
Bu20L5Ph0.83 25.83 77.4 19.4 3.2 75.1 21.4 3.6 
Bu20L15Ph2.5 21.02 53.3 40.0 6.7 56.0 37.7 6.3 
 
However, NMR spectroscopy on the produced powders revealed a lot less leucine content than 
the amount obtained from the back-calculation of the precursor solution composition. Table 7 
below shows the actual leucine content in the produced powders. 
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Table 7. Actual compositions of precursor solutions and their corresponding produced powder 
determined by NMR spectroscopy. Abbreviation: Ctotal, total concentration of precursor 
solution; Pi, Pirfenidone; Bu, Budesonide; L, Leucine; Ph, Phospholipid 
 
Sample Precursor solution Produced powder 
Ctotal 
(g/L) 
Drug 
(w-%) 
L (w-%) Ph (w-
%) 
Drug 
(w-%) 
L (w-%) Ph (w-
%) 
Pi20L0.875Ph0.146 37.50 95.1 4.2 0.7 97.4 0.7 1.9 
Pi20L5Ph0.83 25.83 77.4 19.4 3.2 91.8 0.9 7.3 
Pi20L15Ph2.5 21.02 53.3 40.0 6.7 78.8 0.9 20.3 
Bu20L0.875Ph0.146 37.50 95.1 4.2 0.7 98.6 0.4 1.0 
Bu20L5Ph0.83 25.83 77.4 19.4 3.2 95.6 0.5 3.9 
Bu20L15Ph2.5 21.02 53.3 40.0 6.7 87.8 0.5 11.6 
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5.1.2. Particle morphology 
Figures 16 and 17 below are SEM images showing the surface morphology and structure of 
the drug powders produced with various concentrations of leucine and DPPC. 
 
Figure 16.SEM images of Pirfenidone powders produced at different Leucine concentrations: 
a) Pi20L0.875Ph0.146 b) Pi20L5Ph0.83 c) Pi20L15Ph2.5 
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Figure 17.SEM images of Budesonide powders produced at different Leucine concentrations: 
a) Bu20L0.875Ph0.146 b) Bu20L5Ph0.83 c) Bu20L15Ph2.5 
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5.2. Powder Dispersibility and Particle Size Distribution 
Dispersion experiments performed on the coated drug powders yielded EDs, FPFs and 
coefficient variation of the emitted dose CVs represented in figures 18 to 23 below. All 
experiments were performed at two pressure drops (2kPa and 4kPa) across the inhalers 
(Easyhaler and Twister). The pressure drops 2kPa and 4kPa correspond to inspiratory flow 
rates of 40 l/min and 55 l/min for Easyhaler and 43 l/min and 55 l/min for Twister. 
 
 
 
Figure 18. EDs of Pirfenidone powders at different pressure drops using different inhalers. 
Abbreviation used: EH, Easyhaler; Tw, Twister 
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Figure 19. FPFs of Pirfenidone powders at different pressure drops using different inhalers 
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Figure 20. Variation coefficients of EDs (CVs) of Pirfenidone powders at different pressure 
drops using different inhalers 
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Figure 21. EDs of Budesonide powders at different pressure drops using different inhalers 
 
 
 
 
Bu20L15Ph2.5 Bu20L5Ph0.83 Bu20L0.875Ph0.146
0
1
2
3
4
5
6
ED
(m
g/
d
o
se
)
ED Budesonide powders
2KPa EH
4KPa EH
2KPa Tw
4KPa Tw
 
 
43 
 
 
 
Figure 22. FPFs of Budesonide powders at different pressure drops using different inhalers 
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Figure 23. Variation coefficients of EDs (CVs) of Budesonide powders at different pressure 
drops using different inhalers 
 
Assuming the density of the fine powder particles to be 1g/cm3, their MMAD and GSD values 
were obtained as shown in tables 8 to 11 below. 
Table 8. Dispersion results using Easyhaler with pressure drop of 2 kPa across device 
Sample ED (mg) CVED FPF (%) MMAD (µm) GSD 
Pi20L0.875Ph0.146 2.45 0.07 13.6 5.69 1.77 
Pi20L5Ph0.83 2.34 0.10 30.7 5.48 1.47 
Pi20L15Ph2.5 1.86 0.09 30.0 2.52 1.09 
Bu20L0.875Ph0.146 4.63 0.04 44.5 2.05 1.66 
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Bu20L5Ph0.83 4.01 0.16 50.8 2.33 1.62 
Bu20L15Ph2.5 1.36 0.49 50.4 1.93 1.60 
 
 
Table 9. Dispersion results using Easyhaler with pressure drop of 4 kPa across device 
Sample ED (mg) CVED FPF (%) MMAD (µm) GSD 
Pi20L0.875Ph0.146 2.54 0.08 10.8 6.29 1.73 
Pi20L5Ph0.83 1.95 0.26 34.1 3.61 1.54 
Pi20L15Ph2.5 2.22 0.08 29.5 3.96 1.44 
Bu20L0.875Ph0.146 5.03 0.13 41.9 1.61 1.72 
Bu20L5Ph0.83 4.86 0.09 41.0 2.44 1.68 
Bu20L15Ph2.5 3.98 0.21 44.1 1.87 1.65 
 
Table 10. Dispersion results using Twister with pressure drop of 2 kPa across device 
Sample ED (mg) CVED FPF (%) MMAD (µm) GSD 
Pi20L0.875Ph0.146 3.95 0.61 26.3 5.10 1.39 
Pi20L5Ph0.83 3.11 0.66 31.5 4.08 1.46 
Pi20L15Ph2.5 3.46 0.47 43.4 4.09 1.55 
Bu20L0.875Ph0.146 2.99 0.11 39.5 1.16 1.72 
Bu20L5Ph0.83 2.18 0.58 62.7 1.53 1.69 
Bu20L15Ph2.5 2.19 0.57 48.6 1.42 1.67 
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Table 11. Dispersion results using Twister with pressure drop of 4 kPa across device 
Sample ED (mg) CVED FPF (%) MMAD (µm) GSD 
Pi20L0.875Ph0.146 5.10 0.38 24.9 5.66 1.53 
Pi20L5Ph0.83 4.86 0.49 32.4 4.40 1.49 
Pi20L15Ph2.5 3.51 0.60 47.6 4.10 1.77 
Bu20L0.875Ph0.146 3.73 0.20 36.2 1.19 1.93 
Bu20L5Ph0.83 2.69 0.26 59.8 1.41 1.66 
Bu20L15Ph2.5 3.33 0.14 43.7 1.40 1.65 
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6. DISCUSSION 
 
6.1. Particle Composition and Morphology 
6.1.1. Particle composition 
Fine powder particles were formed by the aerosol flow reactor method and the PVD of leucine 
onto the dried spherical drug particles. When using leucine as a coating material, two main 
features associated with the saturation of leucine are exploited as described above. Table 7 
summarises the compositions of precursor solutions and their respective fine powders. 
Precursor solutions were prepared using a constant leucine/DPPC mass ratio of 6:1. However, 
this leucine/DPPC ratio was not maintained after the aerosol process, as seen in table 7. It is 
observed that there was a tremendous reduction in leucine content in all the powders produced. 
The leucine contents in Pi20L0.875Ph0.146, Pi20L5Ph0.83 and Pi20L15Ph2.5 decreased from 
4.2%, 19.4% and 40.0% in the precursor solutions to 0.7%, 0.9% and 0.9% in the fine powders 
produced, respectively. Similar leucine reductions also occurred in the budesonide powders. 
The leucine concentrations in Bu20L0.875Ph0.146, Bu20L5Ph0.83 and Bu20L15Ph2.5 
dropped from 4.2%, 19.4% and 40.0% in the precursor solutions to 0.4%, 0.5% and 0.5% in 
the fine powders respectively. 
This study was performed at a reactor temperature of 180°C. At this temperature, all of the 
leucine present in the precursor solution may not be completely vaporized. The partial 
evaporation of leucine apart from heterogeneous nucleation and subsequent crystal growth on 
drug particle leads to homogenous nucleation (self-nucleation) of leucine vapour forming small 
nano-sized leucine particles resulting in bimodal size distribution composed of two size 
fractions. These self-nucleated leucine particles formed by are smaller in size than the cut off 
limit of the cyclone used, hence they were not collected by the cyclone.  
Another possible cause of leucine loss in the fine powders could be due to some leucine vapour 
being lost to the internal walls of the reactor. However, this might only be a minor issue. The 
major part of the leucine losses is suspected to have resulted from the homogenous nucleation 
leading to cyclone losses as explained above. These losses affected the leucine/DPPC ratio in 
the produced fine powders and they did not have the 6:1 leucine/DPPC ratio as in their 
precursor solutions. Therefore, the content of leucine by back-calculation method should be 
taken with caution. The actual reason for the losses was not investigated in this work. 
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6.1.2. Particle morphology 
 
Figures 16 and 17 show the SEM images of the leucine coated fine powders with pirfenidone 
and budesonide. The particles in figure 16 looked wrinkled and not perfectly spherical. The 
non-spherical appearance of the particles could be possibly linked to thermodynamics 
properties such melting and glass transition temperature of core drug, pirfenidone. Budesonide, 
being able to withstand high temperatures of over 200°C produced perfectly spherical powder 
particles as seen in figure 17. The budesonide powders were much less agglomerated than the 
pirfenidone powders. At even low leucine concentrations (Figure 16a), there was no 
agglomeration due to the spherical nature of the particles and hence very little surface contact 
of the particles. The little surface contact between some of the particles is not expected to 
negatively affect the powder flowability or dispersibility.  
The pirfenidone powders from figure 16 indicate much more surface contact between the 
particles. However, the presence of the leucine coating on the surface is expected to counteract 
the effect the surface contact might have on the powder dispersibility. The pirfenidone particles 
being non-spherical were also rough on the surface. This means although the particles are in 
close contact with each other, they can be easily dispersed into individual particles with the aid 
of the proper inhalation device. As seen in figure 16, the agglomeration of particles tends to 
increase more with decreasing leucine content. The leucine coating provides the particles with 
some surface roughness to improve the powder flowability. With decreasing leucine 
concentration, there is less roughness and more agglomeration between the particles.  
In figure 17, the leucine coated budesonide powders being perfect spheres also had some 
asperities on the surface. The roughness from the leucine coating is seen to decrease with 
decreasing leucine concentration. 
 
6.2. Powder Dispersibility and Particle Size Distribution 
6.2.1. Powder dispersibility 
ED, CVED and FPF are essential parameters for inhalation therapy. This is because dose 
uniformity or repeatability and powder flowability are determined by the CVED and ED 
respectively. The lower the CVED, the better the dose uniformity or repeatability. Higher ED 
values means better powder flowability. The FPF gives an indication of the powders’ 
dispersibility i.e. deagglomeration, and MMAD and related GSD give an indication of the size 
range of particles being emitted. In carrier-free drug formulations, the results of these 
parameters yield solely from the fine powders’ properties such as shape, size and surface 
roughness. For fine particles within the respirable size range of 1-5µm, the strong inter-
particulate cohesive forces cause the particles to agglomerate, leading to poor powder flow and 
dispersion. The leucine coating on the spherical fine particles formed from the aerosol reactor 
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reduce powder agglomeration and improve the flow. With an improved flow, there is better 
dose uniformity of the drug powder.  
The results are from the experiments performed under two pressure drops (2kPa and 4kPa), 
using two different inhalers (Easyhaler and Twister). The fine powders behaved differently 
with different inhalers and at different pressure drops. All the experiments were performed 
under fast inhalation profiles, where the fine powder emission from the inhalation device was 
completed in 2 seconds. ED of the same powder varied under different pressure drops and also 
with the different inhalers. Using the Easyhaler at a pressure drop of 2kPa, EDs of the fine 
coated powders decreased with increasing leucine content. The powders with the least leucine 
concentration showed the highest ED values. The variation coefficients of these ED values 
(CVED in table 8) were very low; approximately 0.1 in all the fine powders except 
Bu20L15Ph2.5 (whose CVED was almost 0.5). This means the dose delivery were consistent in 
most powders. The lower the CVED, the better the dose uniformity.  
Budesonide powders showed good FPF values which were higher than those of pirfenidone 
powders. The FPF values of the budesonide powders ranged from 44.5% to 50.8%. Pirfenidone 
fine powders, on the other hand showed low FPF values ranging from 13.6% to 30.7%. In both 
cases (pirfenidone and budesonide powders), the powders with least leucine content 
(Pi20L0.875Ph0.146 and Bu20L0.875Ph0.146) had the lowest FPF values, followed by 
powders with highest leucine concentration. Among the pirfenidone fine powders, 
Pi20L5Ph0.83 had the highest FPF value and Bu20L5Ph0.83 had the overall highest FPF value 
in all of the fine powders produced. The budesonide powder with highest leucine content which 
did not perform too well in terms of dose consistency also showed a good FPF of over 50%. 
Using the Easyhaler at a pressure drop of 2kPa, the budesonide powders, even with the least 
leucine concentration showed better dispersibility capabilities than the pirfenidone powders. 
This is due to the well-rounded particles with little inter-particulate surface contact. 
At a higher pressure drop (4 kPa) across the same inhalation device, higher doses of all the fine 
powders were emitted, except for the Pi20L5Ph0.83 powder which had a lower ED when the 
pressure drop was increased. The CVED and FPF values showed similar results to those in table 
8. There was good dose consistency in all powders, even in the Bu20L15Ph2.5 powder. 
Budesonide powders again showed higher FPF (over 40%) than the pirfenidone powders 
(ranging from 10% to 30%). The change in pressure drop across the inhalation device did not 
significantly affect the powders’ dispersibilities.  
In the case of Twister inhaler, the CVED values of the fine powders (ranging from 0.11 to 0.66) 
were higher than from the Easyhaler used at the same pressure drop (table 8). This means there 
was poor dose uniformity when the capsule inhaler was used. In terms of FPF values, 
pirfenidone powders showed better dispersibility with the Twister inhaler than when the 
Easyhaler was used. Bu20L5Ph0.83 powder achieved the highest and best FPF of 62.7% when 
the Twister inhaler was used. This was also the overall highest and best FPF of all the powders 
at both pressure drops and both inhalation devices. The EDs of all the powders was increased 
when the pressure drop was increased from 2kPa to 4kPa. At 2kPa, the EDs of the fine powders 
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ranged from 2.18 to 3.95mg/dose. These values increased when the pressure drop across the 
same device was increased. At 4kPa, the ED values ranged from 2.69 to 5.10mg/dose. The 
CVED values were similar to those at 2kPa with the same inhalation device, Twister (table 10). 
In both tables 10 and 11, CVED values were higher than when Easyhaler was used at the same 
pressure drop. This shows that there was lesser dose uniformity when the Twister inhaler was 
used. FPF values in tables 10 and 11 were quite similar. The change in pressure drop did not 
significantly affect the powder dispersibility. The Twister inhaler again improved the powders’ 
dispersibilities.  
This was especially beneficial to the pirfenidone powders, as they were strongly agglomerated 
and did not show good enough dispersibilities when Easyhaler was used. The particle 
detachment mechanism achieved with the capsule-based inhaler, Twister, also improved the 
flowability (higher EDs) of pirfenidone coated powders which were rather agglomerated. 
 
6.2.2. Particle size distribution 
Generally, particles with MMAD of over 5µm are considered to be too large for deep lung 
deposition. Finer particles with MMAD less than 5µm are often preferred for inhalation 
therapy. Achieving an MMAD of 2-3µm is a frequent goal in formulating inhalation drugs.  
Particles sizes within this diameter are most probable to be successfully inhaled and deposited 
in the deep lungs. A relatively low MMAD coupled with a low GSD indicates narrow particle 
distribution centred on a fine particle size, meaning the particles are better suited for deep lung 
deposition as desired.  
Comparing the different inhalers at the same pressure drops (comparing tables 8 and 10, and 
tables 9 and 11), all the budesonide powders showed a decrease in MMADs with the Twister 
inhaler. However, even with the Easyhaler where the particles could not be detached properly 
upon emission, the particle sizes were still relatively low. MMADs of all budesonide powders 
irrespective of the type of inhaler or the pressure drop ranged from 2.44 to 1.16µm. These 
MMADs were coupled with relatively low GSDs (<2.0) which makes the budesonide powder 
particles most probable to be deposited in the deep lungs. However, the budesonide powders 
with higher leucine contents seemed to have higher MMADs than the powder with least leucine 
content (Bu20L0.875Ph0.146). In all the experiments with both inhalation devices and 
different pressure drops, the Bu20L0.875Ph0.146 powder particles had the lowest MMAD. In 
figure 17, the SEM images of budesonide powders at varying leucine concentrations revealed 
spherical particles with minor inter-particulate surface contact. The powder particles with the 
least leucine content showed much smoother spheres than the powder particles with higher 
leucine content. The leucine coating created surface asperities or roughness on the powder 
particles. In spherical particles with little surface contact, there could be a possibility that the 
asperities created by leucine could interlock with each other as the particles come in close 
contact. Hence more asperities will cause more interlocking of the particles and consequently 
result in slightly larger (higher MMADs) particles being emitted. In the powder with the least 
leucine concentration (Bu20L0.875Ph0.146), there is less leucine coating and hence less 
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asperities which could cause the particles to adhere to each other. This powder yielded particles 
with the lowest MMAD values in all the dispersion experiments performed. The increase in 
MMAD was only slight reaching a maximum of 2.44µm, which is still within the desired range 
(<5µm) for deeper lung deposition. 
In the pirfenidone powders, the SEM images showed agglomeration of the powder particles 
which increased as the leucine concentration reduced. The particles were not as spherical as 
seen in the budesonide powder particles. As a result, there was greater surface contact between 
the pirfenidone powder particles. In this case, the leucine coating (asperities) seemed to help 
to separate the particle agglomerates and hence lower MMADs. The choice of inhalation device 
also affected the MMAD of the particles after emission. The particle detachment mechanism 
of the Twister helped to break particle agglomerates apart. This mechanism helped to bring the 
MMAD values of powders with more surface roughness (Pi20L15Ph2.5 and Pi20L5Ph0.83) 
lower to <5µm. The powder with the least leucine content (Pi20L0.875Ph0.146) had MMAD 
values greater than 5µm even when Twister inhaler was used. This powder had particles with 
much less surface asperities and hence more agglomerated. The particles were also not 
spherical so it was rather difficult for the agglomerates to be detached. 
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7. CONCLUSIONS 
Carrier-free drug formulation with leucine coating have been produced for inhalation therapy 
for poorly soluble drugs. Anti-inflammatory corticosteroid, Budesonide and anti-fibrotic drug, 
Pirfenidone have been used as the APIs. Both of these drugs are soluble in ethanol and their 
precursor solutions were ethanol-based. A small amount (least concentration of the powder 
components) of surfactant, DPPC, was added to the formulation to enhance the powder 
properties. Precursor solutions were prepared at various leucine concentrations for both drugs.  
The aerosol flow reactor method was used to produce spherical drug particles which were 
coated with leucine by PVD. The coated drug powders with varying concentrations of leucine 
were produced and their aerosolization behaviours were investigated in vitro. The 
aerosolization behaviour of the coated fine powders were studied with different inhalation 
devices and at varying pressure drops set across the devices. 
With the same inhaler, pressure drop did not affect dispersibility or FPF, but affects the ED. 
Higher pressure drop emitted higher doses. The choice of inhalation device showed some 
variations in the CVED values. Doses were more uniform (lower CVED) when the Easyhaler was 
used. The use of Twister showed much higher CVED values, which means less repeatability in 
the doses. 
The inhalation device affected the dose uniformity. Experiments performed with reservoir type 
inhaler Easyhaler produced more uniform emitted doses (lower CVED) than capsule single dose 
Twister. Using the Twister inhaler, the CVED values were higher in both pressure drops. This 
means the inhalation device did not provide highly consisted emitted doses. However, the use 
of Twister inhaler improved the powder dispersibility especially in the agglomerated 
pirfenidone powders. The FPFs were higher than when Easyhaler was used. The emission 
technology used by the Twister inhaler helps to break agglomerated particles apart as the 
powder leaves the inhaler mouthpiece.  
Comparing fine powders with same leucine contents in their precursor solutions but with 
different APIs (Pirfenidone and Budesonide), their morphologies were different. The 
Pirfenidone powders being agglomerated affected their aerosolization properties when 
Easyhaler was used. The Budesonide powders, on the other hand, with very spherical particles 
showed good dispersibility as well as particle size distribution with both inhalers. The best 
powder being Bu20L5Ph0.83 with the overall highest FPF (fraction of emitted dose less than 
5µm) had good flowability and particle size distribution at both pressure drops and varying 
inhalers, making it suitable for deep lung deposition. The Pirfenidone powder 
Pi20L0.875Ph0.146 showed the worst aerosoilization properties due to strong particle 
agglomeration and low leucine concentration. Although the Twister inhaler improved the 
aerosolization properties to an extent, this powder still had the lowest FPF and highest MMAD 
of over 5µm. Among the Pirfenidone powders, Pi20L15Ph2.5 showed the best properties with 
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the use of Twister inhaler. FPFs at different pressure drops reached over 40% and MMAD 
values were below 5µm. This same powder also had MMAD values below 5µm with the 
Easyhaler, but FPF not as high as when Twister was used. This formulation may also be suited 
for deep lung deposition. The presence of leucine nanocrystals coated around fine powder 
particles have improved their aerosolization behaviours for pulmonary therapy. The amount of 
leucine required for the best properties varied between the APIs, due to differences in their fine 
particle morphologies. From this work, it has been shown that the aerosol flow reactor method 
is a feasible way to formulate carrier -poorly soluble drugs. Even when the particles were not 
perfectly spherical (as seen in Pirfenidone powders), the leucine coating and presence of DPPC 
improved the powder aerosolization properties.  
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